|
19.07.2010 23:00:00
|
Phase Forward to Lead Sessions at CDISC Interchange Japan 2010
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, will participate at CDISC Interchange Japan 2010, July 20-23 at the Toshi Center Hotel in Tokyo.
At CDISC Interchange Japan, company representatives will lead four sessions on key industry data standards and drug safety related issues:
|
Who: Robbert P. van Manen, Senior Technical Solutions Consultant, Phase Forward |
|||
|
What: "Define.XML - It’s Not Just for Submissions Any More” |
|||
|
When: Tuesday, July 20, 3:30 – 5:00 p.m. JST (Japan Standard Time) |
|||
|
Who: Robbert P. van Manen, Senior Technical Solutions Consultant, Phase Forward |
|||
|
What: "Doing More with SDTM – Safety Signal Detection on Clinical Trial Data” |
|||
|
When: Wednesday, July 21, 9:00 – 10:45 a.m. JST |
|||
|
Who: Joerg Dillert, Principal Consultant, Phase Forward |
|||
|
What: "E2B under the Umbrella of HL7 and BRIDG: Looking To the Future of Data Integrations between Pharmacovigilance (E2B) and Clinical Data Management” |
|||
|
When: Wednesday, July 21, 9:00 – 10:45 a.m. JST |
|||
|
Who: Herve Ouambo, Principal Technical Consultant, Phase Forward |
|||
|
What: "Simplifying Trial Data Extraction with CDISC ODM as a Web Service Interface” |
|||
|
When: Wednesday, July 21, 3:45 – 4:45 p.m. JST |
|||
Phase Forward will also be exhibiting booth #7 at the CDISC Interchange Japan 2010. Members of the media interested in speaking with Phase Forward should contact Maria Sumner at +44 1628 640743 or maria.sumner@phaseforward.com or Juli Greenwood at 781-672-3137 or jgreenwood@chenpr.com.
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.